Listar por autor "Mena-De-Cea, Álvaro"
Mostrando ítems 1-2 de 2
-
Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study
Fernández-Bargiela, Noelia; Rotea-Salvo, Sandra; Margusino-Framiñán, Luis; Balboa-Barreiro, Vanesa; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles; Mena-De-Cea, Álvaro; López-Calvo, Soledad; Vázquez-Rodríguez, Pilar; Míguez-Rey, Enrique; Cid-Silva, Purificación (BMJ, 2020-10-13)[Abstract] Objectives: Despite the high efficacy of antiretroviral treatment, no drug is free from adverse events (AEs). Efavirenz (EFV) and dolutegravir (DTG) are antiretroviral drugs for which neuropsychiatric adverse ... -
Renal profile of patients treated with elvitegravir/ cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort
Rotea-Salvo, Sandra; Martínez-Pradeda, Alejandro; Fernández-Oliveira, Carla; Giménez-Arufe, Víctor; Balboa-Barreiro, Vanesa; Margusino-Framiñán, Luis; Mena-De-Cea, Álvaro; Vázquez-Rodríguez, Pilar; Castro-Iglesias, Ángeles; López-Calvo, Soledad; Martín-Herranz, Isabel; Míguez-Rey, Enrique; Cid-Silva, Purificación (BMJ, 2021-10-14)[Abstract] Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (EVG/c/FTC/TAF) and dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) are currently available for HIV patients. Objectives: This study evaluated ...